MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10637-023-01383-2

Медицинская библиотека · Investigational new drugs · 2023

Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.

Kristeleit Rebecca, Leary Alexandra, Delord Jean Pierre, Moreno Victor, Oaknin Ana, Castellano Daniel, Shappiro Geoffrey I, Fernández Cristian, Kahatt Carmen, Alfaro Vicente, Siguero Mariano, Rueda Daniel, Zeaiter Ali, Awada Ahmad, Santaballa Ana, Zaman Khalil, Sehouli Jalid, Subbiah Vivek

Клиническое исследование II фазыСтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Second-line treatment of endometrial cancer is an unmet medical need. Lurbinectedin showed promising antitumor activity in a phase I study in combination with doxorubicin in advanced endometrial cancer. This phase 2 Basket trial evaluated lurbinectedin 3.2 mg/m2 1-h intravenous infusion every 3 weeks in a cohort of 73 patients with pretreated endometrial cancer. The primary endpoint was overall response rate (ORR) according to RECIST v1.1. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS), safety and an exploratory translational study. Confirmed complete (CR) and partial response (PR) was reported in two and six patients, respectively (ORR = 11.3%; 95%CI, 5.0-21.0%). Median DoR was 9.2 months (95%CI, 3.4-18.0 months), median PFS was 2.6 months (95%CI, 1.4-4.0 months) and median OS was 9.3 months (95%CI, 6.1-12.8 months). Molecular subtypes showed differences in PFS rate at 6 months (p53abn 23.7% vs. "No Specific Molecular Profile" [NSMP] 42.9%) and median OS (p53abn 6.6 months vs. NSMP 16.1 months). The most common treatment-related adverse events (mostly grade 1/2) were fatigue (54.8% of patients), nausea (50.7%), vomiting (26.0%) decreased appetite (17.8%). and constipation, (19.2%). The most common grade 3/4 toxicity was neutropenia (43.8%; grade 4, 19.2%; febrile neutropenia, 4.1%). In conclusion, considering the exploratory aim of this trial and the hints of antitumor activity observed together with a predictable and manageable safety profile, further biomarker-based development of lurbinectedin is recommended in this indication in combination with other agents. Clinicaltrials.gov identifier: NCT02454972.

Для цитирования: Kristeleit Rebecca, Leary Alexandra, Delord Jean Pierre, Moreno Victor, Oaknin Ana, Castellano Daniel, Shappiro Geoffrey I, Fernández Cristian, Kahatt Carmen, Alfaro Vicente, Siguero Mariano, Rueda Daniel, Zeaiter Ali, Awada Ahmad, Santaballa Ana, Zaman Khalil, Sehouli Jalid, Subbiah Vivek. Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.. Investigational new drugs. 2023. DOI: 10.1007/s10637-023-01383-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.